BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

234 related articles for article (PubMed ID: 34520493)

  • 1. Demographic, clinical characteristics and treatment outcomes of immune-complex membranoproliferative glomerulonephritis and C3 glomerulonephritis in Japan: A retrospective analysis of data from the Japan Renal Biopsy Registry.
    Nakagawa N; Mizuno M; Kato S; Maruyama S; Sato H; Nakaya I; Sugiyama H; Fujimoto S; Miura K; Matsumura C; Gotoh Y; Suzuki H; Kuroki A; Yoshino A; Nakatani S; Hiromura K; Yamamoto R; Yokoyama H; Narita I; Isaka Y
    PLoS One; 2021; 16(9):e0257397. PubMed ID: 34520493
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Membranoproliferative glomerulonephritis and C3 glomerulonephritis: frequency, clinical features, and outcome in children.
    Okuda Y; Ishikura K; Hamada R; Harada R; Sakai T; Hamasaki Y; Hataya H; Fukuzawa R; Ogata K; Honda M
    Nephrology (Carlton); 2015 Apr; 20(4):286-92. PubMed ID: 25524631
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical characteristics and outcomes of immune-complex membranoproliferative glomerulonephritis and C3 glomerulopathy in Japanese children.
    Ueda C; Horinouchi T; Inoki Y; Ichikawa Y; Tanaka Y; Kitakado H; Kondo A; Sakakibara N; Nagano C; Yamamura T; Fujimura J; Kamiyoshi N; Ishimori S; Ninchoji T; Kaito H; Shima Y; Iijima K; Nozu K; Yoshikawa N
    Pediatr Nephrol; 2024 Apr; ():. PubMed ID: 38662234
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Therapy and outcomes of C3 glomerulopathy and immune-complex membranoproliferative glomerulonephritis.
    Khandelwal P; Bhardwaj S; Singh G; Sinha A; Hari P; Bagga A
    Pediatr Nephrol; 2021 Mar; 36(3):591-600. PubMed ID: 32886193
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Morphological and etiological analyses of C3 and non-C3 glomerulonephritis in primary membranoproliferative glomerulonephritis using periodic acid-methenamine silver stain electron microscopy: a retrospective multicentered study.
    Honma S; Sato N; Sakaguchi R; Hashiguchi A; Uesugi N; Nakamura Y; Sasano H; Joh K
    Med Mol Morphol; 2024 Mar; 57(1):23-34. PubMed ID: 37823929
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-Term Outcomes of C3 Glomerulopathy and Immune-Complex Membranoproliferative Glomerulonephritis in Children.
    Kirpalani A; Jawa N; Smoyer WE; Licht C;
    Kidney Int Rep; 2020 Dec; 5(12):2313-2324. PubMed ID: 33305125
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinico-pathologic spectrum of C3 glomerulopathy-an Indian experience.
    Viswanathan GK; Nada R; Kumar A; Ramachandran R; Rayat CS; Jha V; Sakhuja V; Joshi K
    Diagn Pathol; 2015 Mar; 10():6. PubMed ID: 25889427
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Outcome of membranoproliferative glomerulonephritis and C3-glomerulopathy in children and adolescents.
    Holle J; Berenberg-Goßler L; Wu K; Beringer O; Kropp F; Müller D; Thumfart J
    Pediatr Nephrol; 2018 Dec; 33(12):2289-2298. PubMed ID: 30238151
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Differences in clinical findings, pathology, and outcomes between C3 glomerulonephritis and membranoproliferative glomerulonephritis.
    Kawasaki Y; Kanno S; Ono A; Suzuki Y; Ohara S; Sato M; Suyama K; Hashimoto K; Hosoya M
    Pediatr Nephrol; 2016 Jul; 31(7):1091-9. PubMed ID: 26846787
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Severe active C3 glomerulonephritis triggered by immune complexes and inactivated after eculizumab therapy.
    Kersnik Levart T; Ferluga D; Vizjak A; Mraz J; Kojc N
    Diagn Pathol; 2016 Oct; 11(1):94. PubMed ID: 27717365
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Diagnostic and Prognostic Comparison of Immune-Complex-Mediated Membranoproliferative Glomerulonephritis and C3 Glomerulopathy.
    Kovala M; Seppälä M; Räisänen-Sokolowski A; Meri S; Honkanen E; Kaartinen K
    Cells; 2023 Feb; 12(5):. PubMed ID: 36899849
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Unraveling the Molecular Mechanisms Underlying Complement Dysregulation by Nephritic Factors in C3G and IC-MPGN.
    Donadelli R; Pulieri P; Piras R; Iatropoulos P; Valoti E; Benigni A; Remuzzi G; Noris M
    Front Immunol; 2018; 9():2329. PubMed ID: 30487789
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Morphofunctional Effects of C5 Convertase Blockade in Immune Complex-Mediated Membranoproliferative Glomerulonephritis: Report of Two Cases with Evidence of Terminal Complement Activation.
    Carrara C; Podestà MA; Abbate M; Rizzo P; Piras R; Alberti M; Daina E; Ruggenenti P; Remuzzi G;
    Nephron; 2020; 144(4):195-203. PubMed ID: 32050203
    [TBL] [Abstract][Full Text] [Related]  

  • 14. C3 glomerulonephritis and dense deposit disease share a similar disease course in a large United States cohort of patients with C3 glomerulopathy.
    Bomback AS; Santoriello D; Avasare RS; Regunathan-Shenk R; Canetta PA; Ahn W; Radhakrishnan J; Marasa M; Rosenstiel PE; Herlitz LC; Markowitz GS; D'Agati VD; Appel GB
    Kidney Int; 2018 Apr; 93(4):977-985. PubMed ID: 29310824
    [TBL] [Abstract][Full Text] [Related]  

  • 15. C5 Convertase Blockade in Membranoproliferative Glomerulonephritis: A Single-Arm Clinical Trial.
    Ruggenenti P; Daina E; Gennarini A; Carrara C; Gamba S; Noris M; Rubis N; Peraro F; Gaspari F; Pasini A; Rigotti A; Lerchner RM; Santoro D; Pisani A; Pasi A; Remuzzi G;
    Am J Kidney Dis; 2019 Aug; 74(2):224-238. PubMed ID: 30929851
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Diagnosis and treatment of glomerular diseases with a membranoproliferative glomerulonephritis (MPGN) pattern of injury].
    Rudnicki M; Windpessl M; Eller K; Odler B; Gauckler P; Neumann I; Zitt E; Regele H; Kronbichler A; Lhotta K; Säemann MD
    Wien Klin Wochenschr; 2023 Aug; 135(Suppl 5):688-695. PubMed ID: 37728653
    [TBL] [Abstract][Full Text] [Related]  

  • 17. C3 glomerulopathy: clinicopathologic features and predictors of outcome.
    Medjeral-Thomas NR; O'Shaughnessy MM; O'Regan JA; Traynor C; Flanagan M; Wong L; Teoh CW; Awan A; Waldron M; Cairns T; O'Kelly P; Dorman AM; Pickering MC; Conlon PJ; Cook HT
    Clin J Am Soc Nephrol; 2014 Jan; 9(1):46-53. PubMed ID: 24178974
    [TBL] [Abstract][Full Text] [Related]  

  • 18. FHR-5 Serum Levels and
    Garam N; Cserhalmi M; Prohászka Z; Szilágyi Á; Veszeli N; Szabó E; Uzonyi B; Iliás A; Aigner C; Schmidt A; Gaggl M; Sunder-Plassmann G; Bajcsi D; Brunner J; Dumfarth A; Cejka D; Flaschberger S; Flögelova H; Haris Á; Hartmann Á; Heilos A; Mueller T; Rusai K; Arbeiter K; Hofer J; Jakab D; Sinkó M; Szigeti E; Bereczki C; Janko V; Kelen K; Reusz GS; Szabó AJ; Klenk N; Kóbor K; Kojc N; Knechtelsdorfer M; Laganovic M; Lungu AC; Meglic A; Rus R; Kersnik Levart T; Macioniene E; Miglinas M; Pawłowska A; Stompór T; Podracka L; Rudnicki M; Mayer G; Rysava R; Reiterova J; Saraga M; Seeman T; Zieg J; Sládková E; Stajic N; Szabó T; Capitanescu A; Stancu S; Tisljar M; Galesic K; Tislér A; Vainumäe I; Windpessl M; Zaoral T; Zlatanova G; Józsi M; Csuka D
    Front Immunol; 2021; 12():720183. PubMed ID: 34566977
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Outcomes of primary nephrotic syndrome in elderly Japanese: retrospective analysis of the Japan Renal Biopsy Registry (J-RBR).
    Yokoyama H; Sugiyama H; Narita I; Saito T; Yamagata K; Nishio S; Fujimoto S; Mori N; Yuzawa Y; Okuda S; Maruyama S; Sato H; Ueda Y; Makino H; Matsuo S
    Clin Exp Nephrol; 2015 Jun; 19(3):496-505. PubMed ID: 25230687
    [TBL] [Abstract][Full Text] [Related]  

  • 20. To interpret and analyze the changing patterns of histology and direct immunofluorescence findings in membranoproliferative glomerulonephritis.
    Nayak PP; Pradhan P; Pradhan D; Mohapatra N; Raman S; Sahoo P
    Indian J Pathol Microbiol; 2024; 67(1):80-85. PubMed ID: 38358193
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.